251111-30-5

Beloranib is a methionine aminopeptidase 2 (METAP2) inhibitor.[1] Beloranib is under development in the treatment of obesity. Administration of beloranib causes profound weight loss in mice, which thereafter achieves ideal body weight. In dogs receiving beloranib, weight loss is associated with improved glycemic control and an apparent reduction in demand for insulin secretion.